Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134080 · ClinicalTrials.gov registry record · Phase 1
FAAH Inhibitor Trial for Adults With Tourette Syndrome
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02134080: Clinical Trial Phase 1 study, sponsored by Yale University.
NCT02134080 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02134080, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this trial is to examine the safety, tolerability and feasibility in the use of a FAAH inhibitor for the treatment of adults with Tourette syndrome.
Primary Outcome
Yale Global Tic Severity Scale (Total Tic Score)
Interventions
- DRUG Placebo
- DRUG PF-04457845
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Why NCT02134080 stopped before completion
NCT02134080 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02134080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02134080 about?
NCT02134080 is a clinical study titled "FAAH Inhibitor Trial for Adults With Tourette Syndrome". The purpose of this trial is to examine the safety, tolerability and feasibility in the use of a FAAH inhibitor for the treatment of adults with Tourette syndrome.
What is the current status of trial NCT02134080?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2014-05. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02134080?
The interventions under investigation include: Placebo (DRUG), PF-04457845 (DRUG).
Who is sponsoring clinical trial NCT02134080?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02134080's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia